Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

• Main Authors: Nogova, Lucia, Sequist, Lecia V, Garcia, Jose Manuel Perez, Andre, Fabrice, Delord, Jean-Pierre, Hidalgo, Manuel, Schellens, Jan HM, Cassier, Philippe A, Camidge, D Ross, Schuler, Martin, Vaishampayan, Ulka, Burris, Howard, Tian, G Gary, Campone, Mario, Wainberg, Zev A, Lim, Wan-Teck, LoRusso, Patricia, Shapiro, Geoffrey I, Parker, Katie, Chen, Xueying, Choudhury, Somesh, Ringeisen, Francois, Graus-Porta, Diana, Porter, Dale, Isaacs, Randi, Buettner, Reinhard, Wolf, Juergen
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Language: English
• Published: AMER SOC CLINICAL ONCOLOGY 2024
• Subjects: Science & Technology; Life Sciences & Biomedicine; Oncology; PROTEIN EXPRESSION; FGFR1; CARCINOMA; SENSITIVITY; NVP-BGJ398; MUTATIONS; DOCETAXEL; NIVOLUMAB; DRIVERS; BLADDER
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/248922
• Institution: National University of Singapore

10.1200/JCO.2016.67.2048